SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences rises as its NCE Usnoflast receives Fast Track Designation from USFDA

28 May 2025 Evaluate

Zydus Lifesciences is currently trading at Rs. 925.25, up by 7.20 points or 0.78% from its previous closing of Rs. 918.05 on the BSE.

The scrip opened at Rs. 922.05 and has touched a high and low of Rs. 926.65 and Rs. 917.40 respectively. So far 19895 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 926.65 and Rs. 880.20 respectively. The current market cap of the company is Rs. 93101.80 crore.

The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.

Zydus Lifesciences’ NCE (novel Chemical Entity) Usnoflast has received ‘Fast Track Designation’ from the United States Food and Drug Administration (USFDA). Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).

A drug that receives Fast Track Designation from the USFDA is eligible for accelerated approval and priority review, if the relevant criteria are met. The purpose of Fast Track Designation is to get important new drugs to the patients faster.

Zydus Lifesciences is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

945.85 6.65 (0.71%)
17-Apr-2026 13:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1230.00
Cipla 1236.55
Zydus Lifesciences 945.85
Lupin 2307.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×